Abiopharma

Artelo Biosciences Announces Positive Interim Phase 2 CAReSResults for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

New Form 6-K - NuCana plc Filed: 2025-09-03 AccNo: 0001193125-25-194556 Size: 20 KB

New Form 424B5 - STRATA Skin Sciences, Inc. Filed: 2025-09-03 AccNo: 0001213900-25-083714 Size: 287 KB

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Coherus Oncology to Participate in Upcoming Investor Conferences

DarioHealth Issues Shareholder Update: Multi-Condition Leadership in Momentum Driven Digital Health Market

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

DarioHealth Issues Shareholder Update: Multi-Condition Leadership in Momentum Driven Digital Health Market